1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline | 122456-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline
• 英文别名: 6-Methoxy-4-methyl-1-(2-methylphenyl)-2,3-dihydropyrrolo[3,2-c]quinoline
• CAS: 122456-25-1
• 化学式: C₂₀H₂₀N₂O
• 分子量: 304.392
• InChiKey: LRRNXUOMUQEWTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 在 钯 silica gel 、 氨 、 二氯甲烷 、 ethyl acetate petroleum ether 作用下， 以 二苯醚 为溶剂， 反应 1.0h， 以gave 1-(2-methylphenyl)-4-methyl-6methoxypyrrolo[3,2-c]quinoline(2.2 g, 48%), m.p. 143°-145°的产率得到8-methoxy-4-methyl-1-(2-methylphenyl)pyrrolo<3,2-c>quinoline
  参考文献：
  名称：

  Dihydropyrrolo quinoline derivatives

  摘要：

  1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂，可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。

  公开号：

  US05051508A1
• 作为产物：
  描述：

  4-chloro-3-(2-chloro-ethyl)-8-methoxy-2-methyl-quinoline 、 2-甲基苯胺 盐酸盐 在 碳酸氢钠 、 silica gel 、 氨 、 二氯甲烷 、 乙醇 作用下， 以 正丁醇 为溶剂， 反应 120.0h， 以gave 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline (2.04 g, 22 %), m.p. 182°-183°的产率得到1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline
  参考文献：
  名称：

  Dihydropyrrolo quinoline derivatives

  摘要：

  1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂，可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。

  公开号：

  US05051508A1

文献信息

• Dihydropyrrolo quinoline derivatives
  申请人：SmithKline Beckman Intercredit B.V.

  公开号：US05051508A1

  公开（公告）日：1991-09-24

  1,4-Substituted 2,3-dihydropyrrolo[3,2-c]quinolines which are inhibitors of H.sup.+ K.sup.+ ATPase activity and useful as inhibitors of gastric acid secretion. A compound of the invention is 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline.

  1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂，可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。
• Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SMITHKLINE BEECHAM INTERCREDIT B.V.

  公开号：EP0307078A1

  公开（公告）日：1989-03-15

  in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂)nOH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

  C₁₋₄烷硫基、C₁₋₄烷酰基、氨基、R⁵至 R⁹相同或不同且各自为氢、C₁₋₆alkyl、C₁₋₆alkoxy、C₁₋₆烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C₁₋₆烷酰基、三氟甲基或硝基，R¹⁰除其他外为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、羟基、-CH₂OH、C₁₋₆烷硫基、NH(CH₂)nOH（其中 n 为 0 至 4）或氨基；和 A 是-(CH₂)₂-、(CH₂)₃- 或-CH=CH-；它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
• US5051508A
  申请人：——

  公开号：US5051508A

  公开（公告）日：1991-09-24
• Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogs of 4-(arylamino)quinolines
  作者：Thomas H. Brown、Robert J. Ife、David J. Keeling、Shiona M. Laing、Colin A. Leach、Michael E. Parsons、Carolyn A. Price、David R. Reavill、Kenneth J. Wiggall

  DOI：10.1021/jm00164a010

  日期：1990.2

  The 4-(arylamino)quinoline 4, previously described as an antiulcer compound, is shown to be an inhibitor of the gastric (H+/K+)-ATPase. It is postulated that 1-arylpyrrolo[3,2-c]quinolines 6 act as conformationally restrained analogues of 4. A series of derivatives of 6 has been prepared and shown to be potent inhibitors of the target enzyme in vitro. Substitution in the ortho position of the aryl ring is important for activity. Unsaturation in the 5-membered ring makes little difference, but introduction of heteroatoms into the same ring markedly reduces activity. In more detailed kinetic experiments, 15c and 4 both show reversible, K(+)-competitive binding to the enzyme, with submicromolar Ki values. The compounds appear to act at the lumenal face of the enzyme and to require protonation for activity. Several compounds in the series are shown to be potent inhibitors of pentagastrin-stimulated acid secretion in the rat.